Global Health
Market cap ₹38,627 Cr
- P/E
- 62.52
- Day range
- ₹1,424.00 – ₹1,467.90
- 52-week range
- ₹956.00 – ₹1,544.00
- Volume
- 1.27 L
- Open
- ₹1,444.20
- Prev close
- ₹1,444.20
Latest results · Q2 FY27(consolidated)Revenue ₹1,469 Cr+33.6%Profit ₹219 Cr+38.3%Margin 14.9%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
MEDANTA in NSE indices and F&O
Research profile
Composite 56 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.6%
- Graham no.
- ₹295.74
- vs Graham
- -79.4%
- ROE ÷ P/B
- 1.7%
- 12-1 mom.
- +4.7%
- Return / vol
- 0.70
- Magic Formula
- #470
- Piotroski
- 5/6
- FCF yield
- -0.7%
- PEG
- 1.63
Appears in 14 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Global HealthMEDANTA | ₹38,627 Cr | 62.52 | 8.91 | 15.1% | 17.0% | 25.0% | 0.31 | +33.7% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 2h agoHeadlines about Global Health from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 59.5
- Price / Book
- 8.92
- ROE (FY26)
- 15.1%
- ROCE (latest year)
- 17%
- Dividend yield
- 0.03%
Moving averages (NSE)
- 20-day
- ₹1,340.45
- Price above
- 50-day
- ₹1,369.35
- Price above
- 200-day
- ₹1,260.6
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Public
- Promoter
- DII
- FII
- Others
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 836 | 809 | 861 | 957 | 943 | 931 | 1,031 | 1,099 | 1,121 | 1,159 | 1,304 | 1,469 |
| Expenses | 620 | 629 | 675 | 728 | 706 | 707 | 784 | 868 | 904 | 915 | 1,017 | 1,099 |
| Operating Profit | 216 | 179 | 186 | 228 | 238 | 225 | 247 | 231 | 217 | 244 | 287 | 370 |
| OPM % | 26% | 22% | 22% | 24% | 25% | 24% | 24% | 21% | 19% | 21% | 22% | 25% |
| Other Income | 18 | 27 | 22 | 18 | 16 | -27 | 20 | 36 | -15 | 37 | 22 | 24 |
| Interest | 18 | 18 | 18 | 16 | 16 | 15 | 14 | 17 | 22 | 27 | 27 | 28 |
| Depreciation | 44 | 45 | 47 | 49 | 48 | 49 | 45 | 50 | 61 | 67 | 69 | 71 |
| Profit before tax | 172 | 143 | 144 | 181 | 189 | 133 | 208 | 200 | 120 | 187 | 213 | 295 |
| Tax % | 28% | 11% | 26% | 28% | 24% | 24% | 24% | 21% | 21% | 24% | 26% | 26% |
| Net Profit | 124 | 127 | 106 | 131 | 143 | 101 | 159 | 158 | 95 | 142 | 157 | 219 |
| EPS in Rs | ₹4.61 | ₹4.74 | ₹3.96 | ₹4.87 | ₹5.32 | ₹3.78 | ₹5.92 | ₹5.89 | ₹3.54 | ₹5.36 | ₹5.90 | ₹8.21 |
From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
0 days since Mar 2021
-13 days since Mar 2021
-49 days since Mar 2021
+36 days since Mar 2021
+41 days since Mar 2021
Strengths, risks & growth
Global Health Limited operates a network of multi-specialty tertiary and quaternary care hospitals under the Medanta brand, primarily across North and East India. The company specialises in cardiac sciences, oncology, neurosciences, digestive and hepatobiliary sciences, orthopaedics, organ transplantation, kidney and urology, and other complex medical procedures. As of June 2026, Medanta operated six hospitals across Gurugram, Lucknow, Patna, Ranchi, Indore and Noida, supported by an expanding diagnostics, pharmacy and outpatient network. [1]
Strengths
- Company has delivered good profit growth of 80.7% CAGR over last 5 years
Risks
- Stock is trading at 8.92 times its book value
Compounded Sales Growth
- 10 Years
- +12%
- 5 Years
- +25%
- 3 Years
- +18%
- TTM
- +26%
Compounded Profit Growth
- 10 Years
- +13%
- 5 Years
- +81%
- 3 Years
- +19%
- TTM
- +11%
Stock Price CAGR
- 10 Years
- —
- 5 Years
- —
- 3 Years
- +17%
- 1 Year
- +19%
Return on Equity
- 10 Years
- —
- 5 Years
- +16%
- 3 Years
- +16%
- Last Year
- +15%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 33.01% | 33.01% | 33.00% | 33.00% | 0.00 pp |
| FII | 10.54% | 10.15% | 9.46% | 9.92% | +0.46 pp |
| DII | 13.99% | 14.76% | 16.89% | 17.01% | +0.12 pp |
| Public | 42.41% | 42.01% | 40.55% | 39.96% | -0.59 pp |
| Others | 0.06% | 0.08% | 0.09% | 0.12% | +0.03 pp |
Filed with NSE for Sept 2026: promoters 33.00%, public 66.88%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 15.99% (-0.06 pp)- Promoters33.0%
- Foreign institutions9.9%
- Mutual funds16.0%
- Insurance0.8%
- Other domestic institutions0.2%
- Retail3.6%
- Others36.4%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Kotak Mid Cap Fund | 2.93% | 1.75% | -0.06 pp |
| Invesco India Midcap Fund | 1.50% | 3.67% | -0.70 pp |
| UTI Flexi Cap Fund | 1.11% | 1.91% | -0.06 pp |
| Invesco India Smallcap Fund | 0.86% | 2.05% | -0.08 pp |
| Invesco India Contra Fund | 0.69% | 1.39% | -0.08 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 30.5%
- Downside volatility
- 28.6%
- Worst 5% of days
- 2.9%
- Average of that tail
- 3.6%
- Max drawdown (1Y)
- 31.2%
- Below its peak
- 4.8%
Against the market
- Beta vs Nifty 50
- 0.75
- Correlation
- 0.33
- Relative strength (3M)
- -2.4%
- ATR (14)
- 3.1%
Return
- Return 1M
- +15.9%
- Return 3M
- +1.5%
- Return 6M
- +15.9%
- Return 1Y
- +21.3%
- vs 200-day average
- +14.0%
Momentum
- RSI (14)
- 62.7
- MACD histogram
- 15.56
- Stochastic %K
- 84.9
- ADX (14)
- 31.2
- +DI / −DI
- 28.6 / 11.8
- Money flow index
- 93.2
Participation
- Delivery (20d avg)
- 55.6%
- vs its 60-day baseline
- +1.6 pts
- Volume vs 20-day
- -0.4σ
- Close vs day's VWAP
- -0.4%
- 52-week position
- 87 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
5 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — passed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — passed
- Asset turnover improving — passed
- Free cash flow
- -₹264 Cr
- FCF yield
- -0.7%
- Cash conversion
- 1.29
- Accruals ratio
- -0.027
- Net debt
- ₹1,056 Cr
- Net debt / equity
- 0.24
- EV / sales
- 7.85
- PEG
- 1.63
- Capex intensity
- 22.2%
- Revenue CAGR
- 35.5%
- Profit CAGR
- 67.1%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- dividendNot available — not reported in this filing
Dividend - Re 0.50 Per Share
14 Aug 2026ex-date - dividendNot available — not reported in this filing
Dividend - Re 0.50 Per Share
22 Aug 2025ex-date
Company announcements
Global Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve Global Health Limited has informed ....
Please find attached herewith the Certificates issued under Regulation 74(5) of the SEBI (Depositories and Participants) Regulation 2018 by RTA for the Quarter ended September 30, 2026.
Intimation Under Regulation 30 of SEBI (Listing Obligation & Disclosure Requirements) Regulation 2015 - ESG Rating assigned by Crisil ESG Ratings & Analytics Limited.
Medanta to expand Healthcare Footprint in Uttar Pradesh with the Acquisition of 10,560 Sq. Meter Land Parcel in Ghaziabad.
Intimation Under Regulation 30 of Listing Regulations.
Intimation regarding closure of Trading Window for the Second Quarter ended on September 30, 2026.
Announcement under SEBI Listing Regulations regarding schedule of Institutional Investor meet.
Intimation under Regulation 30 of Listing Regulations regarding allotment of shares.
Announcement under SEBI Listing Regulations regarding schedule of Institutional Investor meet.
Enclosed Scrutinizer Report and Voting Results of 22nd Annual General Meeting of the Company.
Proceeding of 22nd Annual General Meeting of the Company held on September 16, 2026, at 12:00 Noon.
Announcement under SEBI Listing Regulations regarding schedule of Institutional Investor meet.
Announcement under SEBI Listing Regulations regarding schedule of Institutional Investor meet.
Announcement under SEBI Listing Regulations regarding schedule of Institutional Investor meet.
Announcement under SEBI Listing Regulations regarding schedule of Institutional Investor meet.
Filed with BSE (scrip 543654); the last 45 days. Documents open at bseindia.com.
Documents
Earnings calls
- Nov 2026TranscriptSlidesRecording
- Nov 2026Slides
- Aug 2026TranscriptSlidesRecording
- May 2026TranscriptSlidesRecording
- Feb 2026TranscriptSlidesRecording
- Nov 2025TranscriptSlidesRecording
Credit ratings
- Rating update · 16 Dec 2025 from crisil
- Rating update · 16 Oct 2025 from crisil
- Rating update · 17 Mar 2025 from crisil
- Rating update · 4 Feb 2025 from crisil
- Rating update · 21 Jan 2025 from crisil
- Rating update · 19 Sep 2024 from crisil
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 3 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Global Health: common questions
Answered from the figures on this page.